SWOG clinical trial number
SWOG-9325 (EST-2690)

An Evaluation of the In Vivo Mechanism of Interferon Alfa-2b in the Context of ECOG Trial E1690 (SWOG-9111) Comparing Interferon Administered for 1 Year at High Dosage to Interferon Long-Term Therapy at Lower Dosage as Prophylaxis for High Risk Lymph Node-Metastatic Cutaneous Melanoma, Ancillary. Intergroup

Closed
Phase
Published
Abbreviated Title
An Evaluation of the In Vivo Mechanism of Interferon Alfa-2b in the Context of ECOG Trial E1690 (SWOG-9111) Comparing Interferon Administered for 1 Year at High Dosage to Interferon Long-Term Therapy…
Activated
07/15/1994
Closed
06/01/1995

Research committees

Melanoma

Publication Information Expand/Collapse

2002

Immunomodulatory effects of high-dose and low-dose interferon a2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of Intergroup adjuvant trial E1690

JM Kirkwood;T Richards;HM Zarour;J Sosman;M Ernstoff;TL Whiteside;J Ibrahim;R Blum;S Wieand;R Mascari Cancer 95(5):1101-1112

Editorial: How does interferon work? does it even matter?

VK Sondak Cancer 95(5):947-949

1999

E2690: Intergroup immunological evaluation of IFNa2b dose-response in patients (Pts) with high-risk melanoma.

H Zarour;T Richards;T Whiteside;J Sosman;J Ibrahim;M Ernstoff;R Blum;JM Kirkwood Proc of the American Society of Clinical Oncology 18:538a(#2079)

1995

A study of the mechanism of IFN alfa-2b in high-risk melanoma in the ECOG/Intergroup trial E1690.

JM Kirkwood;J Sosman;M Ernstoff;M Ross;C Gerstner;J Bryant;T Whiteside;C Johnson American Association for Cancer Research 36(#3815):641

Other Clinical Trials

SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
100%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase